Hormonal Therapy and Chemoprevention.

摘要: : Hormone replacement therapy (HRT) can increase the quality as well length of life, but a prolonged use also risk breast cancer. The combination HRT and selective estrogen receptor modulator (SERM) such tamoxifen may retain benefits while reducing risks either agent. A post hoc analysis Italian Tamoxifen Prevention Study showed borderline significant reduction cancer among women who were on continuously compared with continuous users received placebo. Recent studies suggest that standard dose be reduced to one-quarter (i.e., 10 mg every other day) without loss its beneficial biological effects. Since endometrial effect seems both time dependent, could substantially reduce retaining preventive efficacy. On hand, addition containing progestins minimize associated tamoxifen. Moreover, should incidence vasomotor urogenital symptoms, which are major reason for withdrawal in prevention studies. Notably, National Surgical Adjuvant Breast Project (NSABP) P-1 trial, ages 50 or younger had no increased adverse events, including venous thromboembolic events. One possible explanation lack toxicity premenopause is presence adequate circulating levels prevent act an agonist at these target tissues. data from current trial indicate compliance was higher de novo never during study. low doses thus side effects